Abstract:

Objective To investigate the clinical effect of ulinastatin combined with low molecular weight heparin in the treatment of acute pancreatitis. Method 160 patients with acute pancreatitis treated in Beijing Integrated Traditional Chinese and Western Medicine Hospital from February 2015 to March 2021 were randomly divided into two groups, 80 cases in each group. Both groups were routinely treated with gastrointestinal decompression, inhibition of gastric acid and pancreatic juice secretion, antiinflammatory

and rehydration. The control group was additionally treated with low molecular weight heparin calcium, and the observation group was additionally treated with ulinastatin+low molecular weight heparin calcium. The inflammatory factors [interleukin(IL)-1, IL-10, tumor necrosis factor (TNF)-α] and intestinal mucosal barrier related indexes [diamine oxidase (DAO), D-lactic acid and urinary lactulose / mannitol] were observed and compared between the two groups, and the outcome of the disease. Result The levels of IL-1 and TNF -α in the observation group were lower than those in the control group 7 days after treatment. The levels of IL-10 in the observation group were higher than those in the control group (P ＜ 0.05); The levels of Dao, D-lactic acid and urinary lactulose/mannitol in the observation group were lower than those in the control group (P ＜ 0.05); The disease remission rate in the observation group was higher than that in the control group (P ＜ 0.05). Conclusion Ulinastatin combined with low molecular weight heparin in the treatment of acute pancreatitis can help to reduce the

inflammatory response, improve the damage of intestinal mucosa, and is conducive to the remission and benign prognosis of the disease.

Key words: Acute pancreatitis, Ulinastatin, Low molecular weight heparin